在急性冠状动脉综合征中使用胆固醇:系统性审查和元分析
Huey Chiat Cheong1,2, Meng Hsuan Kuo3, Chih-Wei Tseng2,4
1Division of Cardiology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 2, Minsheng Rd., Dalin Township, Chiayi County 62247, Taiwan.
Journal of clinical medicine
|January 10, 2026
概括
在急性冠状动脉综合征 (ACS) 患者中,素可能会减少主要不良心血管事件 (MACE),但不会改善死亡率. 腹等胃肠道副作用是这种抗炎药物常见的.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 急性冠状动脉综合征 (ACS) 具有显著的心血管风险.
- 确定用于ACS管理的有效辅助疗法至关重要.
- 一种抗炎药物 - - 科尔奇辛 (Colchicine) 正在研究其在心血管疾病中的作用.
研究的目的:
- 系统地审查和元分析在ACS患者中对菌素的随机对照试验 (RCT).
- 评估胆固醇在减少主要心血管不良事件 (MACE) 的有效性.
- 评估其对炎症标志物的影响,最佳剂量,时间和安全性.
主要方法:
- 在PubMed,Embase和Cochrane图书馆进行了全面的文献搜索,遵循PRISMA指南.
- 在ACS中纳入15个RCT,其中包括19131名患者,将胆固醇与安慰剂或标准护理进行比较.
- 主要结局:MACE;次要结局:死亡率,心脏病发作,中风,再血管,心力衰竭,CRP/hs-CRP,不良事件.
主要成果:
- 科尔奇辛显示,MACE风险有边际显著的降低 (RR=0.79,p=0.04).
- 对于全因死亡率,心血管死亡率或其他心血管结果,没有发现显著的益处.
- 胃肠道副作用,特别是腹 (RR=1.76,p=0.001),是最常见的不良事件.
结论:
- 在ACS患者中,素可能在降低MACE方面具有潜在的益处.
- 目前的证据不支持其用于改善死亡率或其他心血管结果.
- 胃肠道不耐受是主要问题,需要进一步研究,以获得最佳的患者选择和治疗方案.
相关概念视频
01:30Acute Coronary Syndrome III: Diagnostic Studies
204
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
204
01:28Acute Coronary Syndrome IV: Interprofessional Care
211
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
211
01:30Acute Coronary Syndrome I: Introduction
772
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
772
01:27Coronary Artery Disease V: Interprofessional Care
208
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
208
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
340
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
340
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.3K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.3K